Obesity is an example of an extreme variation of body composition. The physiological changes induced by obesity present the anesthesiologist with many perioperative problems [7], in addition to which these changes also affect the pharmacology of anesthetic drugs.


Cardiac Output Obese Adult Normal Adult Anesthetic Drug Obese Person 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Skrabal F, et al: Equations for the prediction of normal values for exchangeable sodium, exchangeable potassium, extracellular volume, and total body water. British Medical Journal, 1973 2: 37–38.CrossRefPubMedGoogle Scholar
  2. 2.
    Bruce A, et al: Prediction of normal body potassium, body water and body fat in adults on the basis of body height, body weight and age. Scandinavian Journal of Clinical & Laboratory Investigation, 1980: 40: 461–463.CrossRefGoogle Scholar
  3. 3.
    Jung D, et al: Thiopental disposition in lean and obese patients undergoing surgery. Anesthesiology, 1982: 56: 269–274.CrossRefPubMedGoogle Scholar
  4. 4.
    Matteo RS, et al: Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. Anesthesia and Analgesia, 1989: 68: sl91.Google Scholar
  5. 5.
    Schwartz AE, et al: Pharmacokinetics and pharmacodynamics of metocurine in the obese. Anesthesiology, 1986: 65: A295.CrossRefGoogle Scholar
  6. 6.
    Moore FD, et al, “The Body Cell Mass and its Supporting Environment. Body Composition in Health and Disease”, published W.B. Saunders Co., U.S.A., 1963, page 166.Google Scholar
  7. 7.
    Fisher A, et al: Obesity: Its relation to anaesthesia. Anaesthesia, 1975: 30: 633–647.CrossRefPubMedGoogle Scholar
  8. 8.
    Abernathy DR. Greenblatt DJ: Pharmacokinetics of drugs in obesity. Clinical Pharmacokinetics, 1982: 7: 108–124.CrossRefGoogle Scholar
  9. 9.
    Hirsch J, Batchelor B: Adipose tissue cellularity in human obesity. Clinics in Endocrinology and Metabolism, 1976: 5: 299–311.CrossRefPubMedGoogle Scholar
  10. 10.
    Abernathy DR, Greenblatt DJ: Drug disposition in obese humans. An update. Clinical Pharmacokinetics, 1986: 11: 199–213.CrossRefGoogle Scholar
  11. 11.
    Servin F, et al: Propofol pharmacokinetics in morbidly obese patients. Anesthesiology, 1988: 69: A463.CrossRefGoogle Scholar
  12. 12.
    Greenblatt DJ, et al: Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology, 1984: 61: 27–35.PubMedGoogle Scholar
  13. 13.
    Bentley JB, et al: Fentanyl pharmacokinetics in obese and nonobese patients. Anesthesiology, 1981: 55: A177.Google Scholar
  14. 14.
    Bentley JB, et al: Obesity and alfentanil pharmacokinetics. Anesthesia and Analgesia, 1983: 62: 251.Google Scholar
  15. 15.
    Greene NM: The metabolism of drugs employed in anesthesia. Part II. Anesthesiology, 1968: 29: 327.CrossRefPubMedGoogle Scholar
  16. 16.
    Cork RC, et al: General anesthesia for morbidly obese patients — An examination of postoperative outcomes. Anesthesiology, 1981: 54: 310–313.CrossRefPubMedGoogle Scholar
  17. 17.
    De Devitiis O, et al: Obesity and cardiac function. Circulation, 1981: 64: 477–482.Google Scholar
  18. 18.
    Messerli FH: Cardiovascular effects of obesity and hypertension. Lancet, 1982: 1: 1165–1168.CrossRefPubMedGoogle Scholar
  19. 19.
    Rochester DF, Enson Y: Current concepts in the pathogenesis of the obesity-hypoventilation syndrome. Mechanical and circulatory factors. American Journal of Medicine, 1974: 57: 402–420.CrossRefPubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • Gerald M. Woerlee
    • 1
  1. 1.Rijnoord HospitalAlphen aan den RijnThe Netherlands

Personalised recommendations